Founded in 1981. Virchow pioneered the development of novel and innovative API products
based on advances in Chemistry. Virchow business has expanded to serve patients
around the world in supportive of several diseases. Virchow group has good expertise
in the process development of Pharmaceutical and biological products. Our Biotech’s
R&D is efficient in optimizing recombinants and other fermentation derived bio-generics.
Virchow Biotech is filing for U.S.Food and Drug administration’s (FDA) approval for its in house developed advanced wound care products.
Virchow Biotech received Drug control’s (DCGI) approval for conducting clinical trials on periogen, an indigenously developed recombinant therapeutic product for periodontal diseases
Virchow Biotech and Ranbaxy signed an MOU to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment. We are the first in the world to launch this biogeneric product